Tuesday, Oct 29, 2019 9:00a -
Thursday, Oct 31, 2019 5:00p
Revere Hotel Boston Common
200 Stuart Street
Boston, MA 02116
Lectures & Conferences
The potential to target the inflammasome as a therapeutic for many diseases is huge, with rapid advances and excitement in the field, now is the time combine forces and help accelerate development of truly curative inflammasome therapeutics.
The inaugural Inflammasome Therapeutics Summit (ITS) is industry's first dedicated discussion and networking forum focused on bringing together inflammasome thought-leaders to share the latest scientific progress and address the current challenges drug developers are facing. With the mission to bridge the gap between research and drug development and develop clinically effective candidates for inflammatory driven diseases.
Join 60 of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from over 19 expert speakers on latest developments, sharing insights and science to elevate clinically effective inflammasome therapeutic pipelines.
Developed in combination with experts from Nodthera, Pfizer and IFM Therapeutics and other leading organisations, this industry focused forum allows you to determine which diseases the inflammasome is driving and therefore which have the most therapeutic potential commercially and clinically, review the basic biology and mechanisms of action and the use of biomarkers and endpoints for increased efficacy in clinical trials to name a few.
Leave ITS with a deeper understanding of the discovery, preclinical and clinical landscape of inflammasome therapeutics.
Conference and Workshop Day - Standard price for Industry (Early birds available): USD 3199.0,
Conference Only - Standard price for Industry (Early birds available): USD 2299.0,
Conference and Workshop Day - Standard price for Academics (Early birds available): USD 2239.0,
Conference Only - Standard price for Academics (Early birds available): USD 1609.0
Speakers: Steve Glover, Co-founder and Chief Executive Officer, ZyVersa Therapeutics, Ariel Feldstein, Professor and Chief, Pediatric Gastroenterology and Founder, UC San Diego and Jecure Therapeutics, Rebecca Coll, Lecturer in Immunobiology, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Alan Watt, Chief Scientific Officer, Nodthera, Changyun Hu, Senior Scientist, Jounce Therapeutics, Chris Gabel, Vice President, Biology, Nodthera, CJ Barnum, Director of Neurosciences, INmune Bio, Daniel Bachovchin, Assistant Professor, Memorial Sloan Kettering Cancer Center, Davide Povero, Senior Research Scientist, Department of Biochemistry and Molecular Biology, Mayo Clinic Previous Jecure Therapeutics Employee, Erik Hett, Head of Experimental and Chemical Biology, Merck, Hao Wu, Professor, Harvard Medical School, Humayun Sharif, Research Fellow, Harvard Medical School, John Wing, Senior Medical Science Liaison, PTC Therapeutics, Juan Pablo De Rivero Vaccari, Research Assistant Professor, University of Miami Miller School of Medicine, Kate Fitzgerald, Principal Investigator, Umass Medical School, Marcelo Hill, Chief Scientific Officer and Founder, ARDEN ImmunoPharma, Matthew Havrda, Assistant Professor of Molecular and Systems Biology, Dartmouth School of Medicine, Rachel Mak'Anyengo, Product Manager, Novarits, Russell Wyborski, Associate Director, Technical Operations, BioMotiv